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Twodifferent isoforms of the estrogen receptors (i.e., ERα and ERβ)mediate pleiotropic 17β-
estradiol (E2)-induced cellular effects.The ERs are principally localized in the nucleus where
they act by globally modifying the expression of the E2-target genes. The premise that E2
effects are exclusivelymediated through the nuclear localized ERs has been rendered obso-
lete by research over the last 15 years demonstrating that ERα and ERβ proteins are also
localized at the plasmamembranes and in other extra-nuclear organelles.TheE2modulation
of cancer cell proliferation represents a good example of the impact of membrane-initiated
signals on E2 effects. In fact, E2 via ERα elicits rapid signals driving cancer cells to prolifera-
tion (e.g., in breast cancer cells), while E2-induced ERβ rapid signaling inhibits proliferation
(e.g., in colon cancer cells). In this review we provide with an overview of the complex
system of E2-induced signal transduction pathways, their impact on E2-induced cancer
cell proliferation, and the participation of E2-induced membrane-initiated signals in tumor
environment.
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INTRODUCTION
17β-estradiol (E2), themost effective female estrogen, is critical for
the control of a plethora of biological responses that strongly inﬂu-
ence several aspects of male and female physiology. Thus, it is not
surprising that E2 and its estrogen receptors (i.e.,ERα andERβ) are
also considered to be risk factors for the initiation and progression
of several endocrine-related cancers (e.g., breast, prostate, ovar-
ian, and endometrial cancer; Deroo and Korach, 2006). However,
the E2 effects on cancer are often divergent and somewhat con-
trasting depending on the relative levels of the ER subtypes in a
given cancer cell. These contrasting effects relate to the spectacular
complexity of the E2 intracellular signaling triggered by the ERs.
The two ER subtypes are activated when the hormone binds to
the ligand-binding domain (LBD) of the receptors. Upon bind-
ing, several events occur, such as overall conformational changes
of receptors, receptor dimerization, nuclear translocation, and
binding to speciﬁc estrogen response elements (ERE) on DNA.
Ligand-binding favors the receptor interaction with coregulators
(i.e., co-activators and corepressors), which are chromatin remod-
elers that are essential for E2-induced gene transcription (Ascenzi
et al., 2006; Nalvarte et al., 2010; Nilsson and Gustafsson, 2011).
However, the effects of E2 can have a rapid onset. These effects,
mediated by membrane-localized ERα and ERβ, also occur in
tumor environments. Indeed, in cultured cancer cells,membrane-
initiated ERα signaling mediates the proliferative effects of E2
(Acconcia et al., 2005a; Ascenzi et al., 2006; Marino and Ascenzi,
2008),whereasmembrane-initiated ERβ signaling directs the anti-
proliferative effects of E2 (Galluzzo et al., 2007; Marino and
Ascenzi, 2008). In addition, speciﬁc ERα splice variants and inter-
actors, which hyperstimulate extra-nuclear ERα signaling, are
over-expressed in aggressive and metastatic breast tumors (Kumar
et al., 2002; Ohshiro et al., 2010). Moreover, the progressive
reduction in ERβ expression correlates with an increased ERα-
mediated cell proliferation in breast cancer cells (Paruthiyil et al.,
2004) and uncontrolled colon cell proliferation (Galluzzo et al.,
2007; Barone et al., 2010;Warner and Gustafsson, 2010). Nonethe-
less, the role of themembrane-initiated ER signaling in tumors has
been underestimated and, at the present, nuclear ERs localization
(Kumar, 2003; Barone et al., 2010) is considered as both a negative
and positive prognostic factor. The bias concerning the applica-
tion of ER membrane-initiated mechanism(s) as tool in cancer
diagnosis and therapies likely results from experimental evidence
obtained exclusively from in vitro model systems. Thus, the lack
of an in vivo model (i.e., in animal models) questions the physio-
logical relevance for these E2-triggered effects. However, recently,
Shaul and co-workers (Chambliss et al., 2010) showed for the
ﬁrst time that the E2-induced membrane-initiated signals occur
in mice independently of the genomic ER-dependent mechanism.
Therefore, the role of extra-nuclear E2 signaling in the con-
text of a transformed cell (i.e., cancer) needs to be re-evaluated.
In this review, we will give an overview of the complex sys-
tem of E2-induced signal transduction pathways, their impact
on E2-induced cancer cell proliferation, and the participation of
E2-induced membrane-initiated signals in tumor environment.
THE STRUCTURE OF THE ESTROGEN RECEPTORS
The ERα and the ERβ are ligand-activated nuclear receptors,
which have a high degree of sequence homology and a similar
three-dimensional structure. In particular, the ERs are modu-
lar proteins composed of six functional domains. Each domain
has autonomous functions: the N-terminal portion (A/B domain)
plays a role in protein–protein interactions and in the activation of
gene transcription; the DNA binding domain (DBD), also known
as the C domain, directs receptor dimerization and binding to
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DNA in the gene promoters containing the ERE; the D domain,
whichworks as an hinge and also contributes to receptor dimeriza-
tion, is the binding site for the heat-shock proteins (Hsp); and the
C-terminal domain contains the LBD or E domain, which is now
recognized to bind E2 and to cooperate with the A/B domain in
synchronizing gene transcription. Although the function of the C-
terminal portion of the receptor still remains obscure, the so-called
F domain can also modulate ER transcriptional activity (Ascenzi
et al., 2006).
Two distinct transcription activation functions (AFs) have been
identiﬁed for the ERs. The AF-1 region is localized within the N-
terminal portion (A/B domain) and is able to regulate ERE-based
gene transcription, even in the absence of ligand. Furthermore,
the C-terminal AF-2 region mediates ligand-dependent transcrip-
tional activation by E2. Interestingly, both AFs coordinate gene
transcription by dictating the pattern of association of the ERs
with either co-activators or corepressors (Lonard and O’Malley,
2007; O’Malley and Kumar, 2009). In addition to E2, the ERs
can bind to diverse natural and synthetic molecules, which are
now considered to be exogenous ERs ligands [e.g., selective estro-
gen receptor modulators (SERMs), endocrine disruptors; Ascenzi
et al., 2006]. Notably, the use of these ligands led to the deﬁnition
of the ERs as highly allosteric proteins and offered the opportunity
to design drugs that target the ERs in the treatment of E2-related
diseases, such as cancer (Ascenzi et al., 2006).
In addition to full-length ERs, numerous truncated forms of
the ER exist, resulting from alternative mRNA splicing; these ERs
have been found in a number of normal and pathological tissues
and are frequently co-expressed with their full-length counter-
parts. Moreover, ER degradation peptides (e.g., ERα17p) have also
been discovered (Pelekanou et al., 2011). The exact function and
potential physiological role of the truncated forms and receptor
fragments of ERα and ERβ in human disease remain to be eluci-
dated (Ascenzi et al., 2006; Herynk and Fuqua, 2004), but evidence
indicates that these shorter ERs (e.g., ERα36; ERαV; ERa46; ERβcx;
ERαp17) can differentially modulate E2 signaling, impact target
gene regulation and, consequently, be involved in tumor growth
and progression (Li et al., 2003; Penot et al., 2005; Wang et al.,
2005, 2006; Koduri et al., 2006; Galluzzo et al., 2007; Lee et al.,
2008; Ohshiro et al., 2010; Pelekanou et al., 2011).
ESTROGEN RECEPTOR-BASED SIGNAL TRANSDUCTION
The initial cloning of ERα (Green et al., 1986; Greene et al., 1986)
and ERβ (Kuiper et al., 1996; Gustafsson, 1999) has led to changes
in the interpretation of the E2 molecular mechanism. Thus, it is
nowknown that bothER isoforms share the samemolecular action
mechanisms (Ascenzi et al., 2006).
ERα and ERβ are transcription factors that directly bind DNA
to regulate gene transcription (i.e., direct genomic mechanism).
The regulation of gene transcription occurs by receptor cycling on
and off their DNA binding sites (i.e., ERE sequence). The binding
of E2 stabilizes these transient receptor: DNA complexes making
possible mRNA production (Métivier et al., 2003; Reid et al., 2003;
Picard et al., 2008).
ERs mediate transcription via tethered interactions through
protein–protein interactions with other transcription factors
[e.g., activating protein-1 (AP-1), stimulating protein-1 (Sp1)] to
activate gene expression (i.e., indirect genomic mechanism;
Ascenzi et al., 2006).
Both ERα andERβ aremembrane-tethered proteins. Themem-
brane localization of the ERs allows the occurrence of the rapid
effects of E2 (i.e., extra-nuclear mechanism; Hammes and Levin,
2007; Marino and Ascenzi, 2008).
Therefore, E2 molecular mechanisms are strictly dependent on
the intracellular localization of the ERs. However, it should be
noted that although both the nuclear and membrane-initiated ER
activities can be studied independently, the cognate hormone E2
triggers both of these activities. Thus, both ER activities must
occur simultaneously and be intertwined in vivo. In turn, the
de-regulation of one of either nuclear or membrane-initiated ER
activities will irremediably impact the other, with potential patho-
logical consequences. The challenge is to understand themolecular
details that allow their synergy. The post-translational modiﬁca-
tions of ERα and ERβ and the selective association of the ERs
with speciﬁc interactors appears to be a mechanism for cells to
ﬁnely tune and integrate nuclear and extra-nuclear ER signaling
(Marino and Ascenzi, 2008; La Rosa et al., 2011).
THE GENOMIC MECHANISM
It is a well-known fact that in ER-expressing cells, the non-
activated ERs are associated in the cytoplasm with the Hsp (e.g.,
Hsp90, Hsp70, and Hsp56). Upon E2 binding, allosteric tran-
sitions occur in the ER, the Hsps dissociate and the receptors
translocate to the nucleus, where ERE-based gene transcription
occurs by recruiting cofactor proteins (i.e., co-activators and
corepressors), and the basal transcription machinery (Kumar and
Chambon, 1988; McKenna and O’Malley, 2001; Ascenzi et al.,
2006; Lonard and O’Malley, 2007; O’Malley and Kumar, 2009).
The co-activators interact with the ERs through their leucine-
(L)-rich motifs (i.e., LXXLL, where X is any amino acid; e.g.,
SRC-1) and facilitate ER transcriptional activity by triggering
chromatin remodeling (e.g., CBP/p300 PRMT1, SWI/SNF), RNA
polymerase II activation, and linking the ERs to the basal tran-
scription machinery (Ascenzi et al., 2006), whereas corepressors
[e.g., histone deacetylases (HDAC)] prevent ERs from inducing
gene transcription (Jepsen and Rosenfeld, 2002).
In the nucleus, ERα cycles on and off the ERE-containing gene
promoters. Although this process occurs even in the absence of
E2, E2 shifts these coordinated and transcriptionally unproduc-
tive ERα–DNAassociation/dissociation cycles toward a productive
transcriptional response (Métivier et al., 2003; Reid et al., 2003).
Interestingly, the discovery that E2-activated ERβ possesses a sim-
ilar cyclic nature (Picard et al., 2008) indicates that this molecular
circuitry is conserved. Therefore, the de-regulation of any step
of the transcriptional cycle (e.g., alteration in ER: co-activators
interaction) could lead to malignant transformation (Lonard and
O’Malley, 2006).
In addition to direct interaction with ERE, ERs can regu-
late gene transcription without directly binding to DNA. In this
indirect genomic mechanism, ERα associates with speciﬁc tran-
scription factors, such as Sp1 and AP-1, which play an impor-
tant role in the transcriptional activation of multiple growth
regulatory genes in breast cancer cells. ERβ/Sp1 is primar-
ily associated with decreased ligand-dependent gene expression
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(Safe, 2001; Pearce and Jordan, 2004). The interaction between
ERs and nuclear factor-κB induces the E2-mediated inhibition of
gene transcription (Ascenzi et al., 2006).
THE EXTRA-NUCLEAR MECHANISM
The nuclear actions of E2 occur after at least 2-h time lag post-
E2 stimulation (Métivier et al., 2003; Reid et al., 2003) and explain
someE2 functions inphysiological andpathological situations (see
Farach-Carson and Davis, 2003; Ascenzi et al., 2006). However,
E2 elicits some cellular effects that are too rapid (i.e., in seconds
to minutes) to be mediated by the activation of the nuclear ERs
(Szego and Davis, 1967). These effects are refractory to transcrip-
tion and translation inhibitors (Losel et al., 2003) and are induced
by membrane-impermeable E2 conjugates (e.g., E2-BSA; Ascenzi
et al., 2006). The E2-evoked rapid signals involve the activation
of several signal transduction pathways (e.g., phospholipase C
(PLC)/protein kinase C (PKC); Src/extracellular-activated kinase
(ERK), phosphatidyl-inositol 3 kinase (PI3K)/AKT, p38/mitogen-
activated protein kinase (MAPK); Janus kinase/signal transducers
and activators of transcription (JAK/STAT); p21-activated kinase
1 (Pak1); casein kinase I-g2; sphingosine kinase; RhoA/ROCK-
2/moesin; Losel et al., 2003; Ascenzi et al., 2006; Hammes and
Levin, 2007; Sanchez et al., 2009) in E2-sensitive cells, and some of
these signaling pathways could be cell type speciﬁc. Interestingly,
both ERα and ERβ trigger the activation of the rapid E2-induced
effects although there appears to be some degree of speciﬁcity in
the isoform-mediated extra-nuclear signaling.
Remarkably, accumulating evidence identiﬁes at least two con-
served pathways in membrane ERα-based E2 rapid signaling. The
E2-dependent activation of the ERK component of the MAPK
family and the AKT kinase in the PI3K axis occur in a variety
of normal or transformed cell lines (e.g., vascular or epithe-
lial cells; breast cancer cell; hepatoma cells). The mechanism
by which the E2–ERα complex activates these two transduc-
tion pathways involves the E2-induced association of membrane
ERα with several proteins involved in the ERK/MAPK pathway
(i.e., Shc, Src, Ras) leading to Shc/Src/Ras/ERK activation (Song
et al., 2004) and the PI3K/AKT pathway [i.e., p85, integrin-linked
kinase (ILK), glycogen synthase kinase 3β (GSK3β)] leading to
PI3K/ILK/AKT/GSK3β activation and nitric oxide (NO) release
(Simoncini et al., 2000; Medunjanin et al., 2005; Acconcia et al.,
2006). Interestingly, in cancer cells either signaling cascade trans-
duces the E2 proliferative and anti-apoptotic effects bymodulating
E2-induced DNA synthesis, resulting in cell cycle progression and
cell proliferation (Marino et al., 2002, 2003; Song et al., 2004) as
well as cell migration (Acconcia et al., 2006).
The ability of the E2–ERβ complex to activate rapid extra-
nuclear mechanisms has received less consideration. Our work
identiﬁed the E2-dependent activation of the p38 component of
theMAPK family as a conserved pathway inmembrane ERβ-based
E2 rapid signaling. Indeed, the E2-induced ERβ-mediated activa-
tion of the p38/MAPK occurs in ERβ-transfected HeLa cells and
in ERβ containing rat myoblasts, colon adenocarcinoma cells, and
neuroblastoma cells (Acconcia et al., 2005a; Galluzzo et al., 2007,
2009; De Marinis et al., 2010). In any case, the E2-dependent acti-
vation of the p38/MAPK pathway requires the physical association
between membrane ERβ and p38 and results in triggering the E2
anti-proliferative and pro-apoptotic effects in colon cancer cell
lines (Galluzzo et al., 2007).
The data reported here strongly demonstrate that the
membrane-initiated effects of E2 can regulate different and oppo-
site cellular processes, such as proliferation, survival, apoptosis,
and are operative in transformed and malignant cells. Moreover,
they represent conserved molecular circuitries by which E2 exerts
its pleiotropic effects through the ERα and the ERβ. In turn, the
de-regulation of ERα- and ERβ-mediated rapid signal transduc-
tion would lead to pathological consequences, such as cancer. In
this respect, it is noteworthy that ERα-positive breast tumors are
treated with drugs aimed at interfering with the availability of
endogenous E2 (e.g., aromatase inhibitors) or ERα transcriptional
activity (e.g., 4OH-tamoxifen; Keen and Davidson, 2003). The
same drugs also act on the ERβ rapid signaling, but not because
ERβ expression is inversely correlated with the development of
several cancer (i.e., breast and colon cancer; Marino and Ascenzi,
2008; Barone et al., 2010; Warner and Gustafsson, 2010).
Therefore, one would expect this mechanism to be highly
regarded as a target for cancer prevention or treatment. How-
ever, this is not the case most likely because of concerns about the
way the membrane-initiated effects of E2 are elicited after E2–ER
engagement.
Membrane localization of the estrogen receptors. The rapid ER
signaling of the E2 requires an ER to be localized at the plasma
membrane. Although more that 2000 publications dealing with
membrane localization of ERs and rapid extra-nuclear effects of
E2 appeared in scientiﬁc databases over the past 40 years, this area
of research is highly debated. Accordingly, because ERs belong to
a nuclear receptor superfamily, a dogmatic assumption dictates
that the effects of E2 can be mediated exclusively through the
transcriptional actions of the nuclear localized ER. This statement
refers to some classic doubts about the reasons why cells would
have evolved a mechanism to localize a nuclear receptor at the
plasma membrane.
It is now accepted that ERs are localized at the plasma mem-
brane of E2-sensitive cells. After the initial discovery in 1967 that
E2 administration to an ovariectomized rat triggers the rapid
increase (15 s) in cAMP levels (Szego and Davis, 1967), speciﬁc
plasma membrane binding sites for E2 were ﬁrst identiﬁed in 1977
at the surface of endometrial cells (Pietras and Szego, 1977) and
later,were also demonstrated at the breast cancer cell plasmamem-
brane (Berthois et al., 1986). However, it was only in the late 90s
that a panel of antibodies were created against multiple epitopes
of nuclear ERα that were also able to recognize the membrane ERα
(Pappas et al., 1995); antisense oligonucleotides directed against
the nuclear ERα also caused a decrease in the expression of mem-
brane ERα (Norﬂeet et al., 1999) and the ectopic expression of
ERα cDNA in ER null cells resulted in both nuclear and mem-
brane localization of ERα (Razandi et al., 1999). More recently, a
protein of the same size of the recombinant ERαwas isolated from
the breast cancer cell membrane, detected by ERα antibodies and
then subjected to mass spectrometry. The peptides that resulted
from tryptic digestion were scored as 100% identical to classical
human ERα (Pedram et al., 2006). Therefore, the nuclear ERα is
identiﬁed as the receptor form at the plasma membrane.
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Nonetheless, there is also accumulating evidence that E2 binds
to other receptors belonging to an entirely different family of pro-
teins. The G-protein-coupled and seven-transmembrane recep-
tor, GPR30, is recognized to be an estrogen receptor (Prossnitz
et al., 2008; Maggiolini and Picard, 2010), even if this assump-
tion continues to be seriously disputed (Levin, 2009; Otto et al.,
2009). GPR30 is widely expressed in carcinoma cell lines includ-
ingER-positiveMCF-7 andER-negative SK-Br3 breast cancer cells,
endometrial cancer cells, ovarian cancer cells, and thyroid carci-
noma cell lines (Maggiolini and Picard, 2010). Although these data
suggest a connection of GPR30 to cancer, larger sample sizes with
more measured parameters and patient follow-up are needed. In
addition, the GPR30 gene has not emerged in gene expression
signatures for aggressive breast cancer nor has it scored as a hit
in functional screens for genes contributing to 4OH-tamoxifen
resistances in breast cancer cells (Maggiolini and Picard, 2010).
Therefore, GPR30 signaling will not be analyzed here.
The fact that the amount of the ERs at the plasma membrane
is approximately 5–10% of the endogenous ER cellular content
has raised questions concerning the physiological importance of
E2 rapid signals. Nonetheless, the membrane localization of ERs
is necessary and sufﬁcient for the activation of the E2 membrane-
initiated signals because the inhibition of these membrane-
mediated events prevents E2-triggered mitogenic, motile, and
apoptotic responses (Acconcia et al., 2006; Hammes and Levin,
2007; Marino and Ascenzi, 2008). Moreover, it is interesting to
note that upon E2 administration, only 5–10% of the endogenous
cellular ERs are activated (Leclercq et al., 1986). Thus, it is tempting
to speculate that upon E2 binding, the membrane receptor signals
and shuttles into the nucleus where it also triggers gene transcrip-
tion. From an evolutionary standpoint, the presence of plasma
membrane ERswould have given the selective advantage to rapidly
respond to the changes in the concentration of the lipophilic hor-
mone (i.e., E2) in the extra-cellular environment. This mechanism
would avoid the necessity for E2 to directly engage the nuclear ER,
which is shielded by two bilayermembranes.Although this process
is inconsistent with the classic notion of E2 entry into target cells,
which is known as the “free” hormone hypothesis (Adams, 2005),
data regarding an active transport mechanism for E2 cellular
uptake are accumulating (Pietras and Szego, 1984; Hammes et al.,
2005).Moreover, the recent discovery that E2 is stably inserted into
the plasma membrane and can ﬂip within the lipid bilayer without
escaping it (Scheidt et al., 2010) further supports the notion for an
active transport mechanism for E2 internalization.
Interestingly, the ERs do not possess any intrinsic transmem-
brane domain, thus a great experimental effort was undertaken to
understand the molecular determinants required for the mem-
brane localization of the ERs. At present, three main mecha-
nisms have been identiﬁed for the plasma membrane localization
of ERs, including the association with resident membrane pro-
teins, the interaction with transmembrane receptors and lipid
modiﬁcation.
Membrane ERα and ERβ are localized in caveolae (Razandi
et al., 2002) or in other membrane raft structures (Márquez
et al., 2006). The caveolae localization of the ERs is mediated
by the direct physical interaction of ERs with caveolin-1. Indeed,
cells lacking caveolin-1, but containing ERs, show only nuclear
localization of the receptors. Consistent with this evidence, expres-
sion of exogenous caveolin-1 in this cell context results in a small
population of ERs localizing at the plasma membrane (Razandi
et al., 2003). The localization of ERα to non-caveolae lipid rafts
was also recently shown to be dependent on a direct association
of the receptor with the raft protein ﬂotillin-2. Interestingly, this
peculiar ERα raft localization appears to modulate downstream
nuclear events leading to cell growth (Márquez et al., 2006).
Furthermore, the interaction of ERα with speciﬁc membrane
receptor tyrosine kinases, such as HER-2 (Yang et al., 2004) and
IGF-1R (Song et al., 2004), is also a mechanism for the mem-
brane localization of the ERα. Interestingly, because ERs do not
display any intrinsic kinase activity, the membrane association
with growth factor receptors is thought to allow ERα to recruit
signaling molecules (e.g., p85) required for the activation of
phosphorylation cascades (Marino and Ascenzi, 2008).
The palmitoylation (i.e., protein modiﬁcation with palmitic
acid) is a post-translational modiﬁcation that directs full-length
ERα and ERβ to the plasma membrane (Acconcia et al.,
2005b; Galluzzo et al., 2007). The palmitoylation of ERα and
ERβ, which occurs within the E domain of the receptors, is
required for receptor membrane localization and interaction with
caveolin-1, activation of E2 rapid signaling, and the completion
of the downstream physiological processes (Acconcia et al., 2005b,
2006; Galluzzo et al., 2007; Marino and Ascenzi, 2008).
However, the mechanism of the E2-dependent modulation of
ER association with plasma membrane is still not completely
understood. E2 induces the de-palmitoylation of both ERα and
ERβ (Acconcia et al., 2005b; Galluzzo et al., 2007), but the subse-
quent downstream effects are different for ERα and ERβ. Indeed,
the E2-activated ERα dissociates from caveolin-1 and is re-located
to other membrane proteins (i.e., HER-2 and IGF-1R; Song et al.,
2004; Yang et al., 2004), whereas the E2-activated ERβ further
associates with caveolin-1 and to the p38/MAPK (Galluzzo et al.,
2007). Following E2-mediated de-palmitoylation, rapid ERα and
ERβ signals occur and are required to induce E2-evoked cell pro-
liferation (Acconcia et al., 2005b) or apoptosis (Galluzzo et al.,
2007). Thus, while palmitoylation is critical to locate the ERs at
the plasma membrane, the E2-dependent modulation of this post-
translational modiﬁcation provides the basis for the differential
effects of E2 as both an oncogenic molecule for breast cancer (i.e.,
ERα signaling) and a protective factor for colon cancer (i.e., ERβ
signaling).
ROLE OF THE MEMBRANE-INITIATED MECHANISMS IN
TUMORS
Only limited information is available concerning the occurrence
of the aforementioned conserved molecular circuitries in vivo and
thus, even less proof of their de-regulation in tumor samples is
evident. Nonetheless, evidence that demonstrates the presence of
the membrane-initiated E2 effects in vivo exists and can no longer
be ignored. As a consequence, their importance in carcinogenesis
needs to be re-evaluated.
EVIDENCE FOR IN VIVO MEMBRANE-INITIATED E2 EFFECTS
Careful inspection of the literature reveals that the discovery that
E2 elicits rapid effects in vivo was reported (Szego and Davis,
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1967) soon after the formal deﬁnition that the sex steroid hormone
E2 acts through a receptor protein (Jensen, 1965), but before the
formulation of the concept that steroid hormones acted on DNA
to regulate gene transcription (O’Malley and McGuire, 1968); the
intravenous administrationof physiological doses of E2 toovariec-
tomized rats induces within 15 s a dramatic increase of uterine
cyclic AMP, which lasts for 5min and is reduced to basal levels
within 1 h. Interestingly, these effects are mimicked by another
estrogenic molecule (i.e., diethylstilbestrol) and are unaffected
by 17α-estradiol. The physiological relevance of this is apparent
because there is early evidence of estrogenic stimulation, includ-
ing the liberation of sequestered histamine and the accompanying
expansion of the microcirculation and associated alterations in
membrane functions (Szego and Davis, 1967).
When the multifaceted and intertwined nature of ERs signal-
ing network was already known, the group of Dr Jameson Jakacka
et al., 2002 created a mouse model in which a point mutation was
created in the ﬁrst zinc ﬁnger of the DBD of the endogenous ERα.
This mutation (E207A/G208A in mouse ERα) abolishes receptor
to ERE binding and the activation of ERE-containing reporter
genes, but preserves all the other ERα-based signals (Jakacka et al.,
2002; Pedram et al., 2009). The analysis of the phenotype for the
ER knock-in mouse model revealed that the knock-in female mice
are infertile; indeed, their ovaries did not contain any corpora
lutea and the stromal cells contained abundant lipid droplets. In
addition, the uteri were enlarged with a clear evidence of cys-
tic endometrial hyperplasia, whereas the mammary glands were
hypo-plastic (Jakacka et al., 2002). Because the ERα knock-in mice
phenotypes were signiﬁcantly different from the ERα knock-out
mice phenotypes, the observed defects demonstrate the complex-
ity of the E2 signaling in whole-animal physiology and highlight
how the extra-nuclear ERα signaling modulates different E2-
dependent effects in different tissues. Interestingly, the alteration
in the steroidogenesis (i.e., fat accumulation in ovary stromal
cells) in the ERα knock-in mouse model is phenocopied by the
accumulation of abdominal visceral and other depots of fat (i.e.,
overall increased body weight),which is observed in the transgenic
mice expressing only a functional E domain of ERα at the plasma
membrane (Pedram et al., 2009). Thus, the fact that E2 deter-
mines such a dramatic imbalance in the female mice physiology
by acting on ERα, which is incapable to trigger ERE-mediated E2-
induced gene transcription, and on the E domain of the receptor,
which is critical for extra-nuclear E2 signaling activation, further
demonstrates the activity of the membrane-initiated ERα path-
way in vivo (Jakacka et al., 2002; Pedram et al., 2009). Nonetheless,
although both ERα knock-in mice and transgenic ERα E domain
mice retain the E2-induced activation of ERK/MAPK and AKT
as the wild type counterparts, the analysis of their phenotype
demonstrates that the nuclear ERα is critical for normal devel-
opment in mice (Jakacka et al., 2002; Pedram et al., 2009), thus
conﬁrming that there is bothnuclear andmembrane-initiatedERα
signaling cross-talk in vivo. Unfortunately, none of these stud-
ies analyzed whether these animals were more or less prone to
develop tumors. Considering that ERα membrane-initiated sig-
nals are critical for DNA synthesis and cell cycle progression, one
might expect an increased incidence in tumors in at least some
E2-sensitive tissues.
Chambliss et al. (2010) recently used a more physiological
approach to demonstrate that activation of rapid, membrane-
initiated ERα signals is important in vivo. The use of an E2-
dendrimer conjugate, that activates membrane-associated ERs,
but excludes them from the nucleus (Harrington et al., 2006),
revealed that, in vivo, the vascular protective effects of E2 are medi-
ated exclusively through membrane-initiated ERα signal pathways
(Chambliss et al., 2010). These data are, of course, extremely
important because they represent the ﬁrst demonstration that
extra-nuclear E2-mediated effects are operative in mice. In turn,
this evidence gives the opportunity to pharmacologically target
extra-nuclear E2 signaling in vivo through the development of
extra-nuclear speciﬁc drugs. Nonetheless, the E2-dendrimer con-
jugates are synthetic and the presence of the dendrimer may
render the interpretation of the data incomplete. For this rea-
son, understanding how a non-membrane localized receptor (e.g.,
the palmitoylation-defective mutant) works in vivo under the
stimulation of the physiological hormone remains a critical issue.
Finally, it is important to note here that an in vivo model in
which the ERβ is manipulated to study its membrane-initiated
signals is not available at the present. Moreover, caution should
be used in the interpretation of the abovementioned data because
they were all studied in an ERβ-wild type background.
EVIDENCE FOR EXTRA-NUCLEAR E2 EFFECTS IN CLINICAL PRACTICE
As the emerging data concerning membrane ERs signaling facil-
itates our understanding of E2 actions, the integration of this
information with the clinic-pathological data of patients becomes
imperative. For themoment,only nuclear ERs localization tests are
utilized in daily hospital practices to obtain predictive diagnosis
and to choose pharmacological therapies.
However, at least for breast cancer, mounting evidence points
to the expression of the membrane ERα as a tumor exclusivity.
In fact, the adjacent non-cancerous tissues are negative for mem-
brane ERα (Kampa et al., 2008). Interestingly, the analysis of 219
primary breast cancers by immuno-histochemical staining reveals
that membrane ERα is detected in 34% of the cases in which the
tumor is classiﬁed as ERα-negative on the basis of the ERα nuclear
expression. Moreover, breast tumor samples, expressing mem-
brane ERα, also display a positive correlation with phosphorylated
AKT and HER-2 over-expression (Kim et al., 2006). Remark-
ably, another study reports that, in ERα-positive breast specimens
derived from patients after surgical resection, the plasma mem-
brane localized ERα is phosphorylated on the serine residue 118
(i.e., activated), whereas it is absent from normal breast tissue.
The phosphorylated, membrane-bound ER appears to deﬁne the
“invasive carcinoma state” in human fresh tissue specimens
because the analysis of the downstream signaling pathways in the
cytosol of the same samples shows an hyper-activated status of the
signaling kinases ERK/MAPK and AKT, which is correlated with
an increase in anti-apoptotic signals (Mintz et al., 2008). Further-
more, other phosphorylated forms of the ERα have been found
in tumors but their correlation with membrane-initiated signal-
ing was not studied (Murphy et al., 2011). Data concerning the
expression of membrane ERs in tumor specimens are limited to
ERα, while no studies for membrane ERβ in tumor samples have
been performed.
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Nonetheless, at present, the mechanism by which an increased
fraction of the activated ERα is localized at the cell plasma mem-
brane in the tumor cells is still not known. De-regulation of
the enzyme that palmitoylates receptors may, however, account
for it. In addition, activated ERα can be forced to localize out-
side the nucleus and/or in close proximity of the plasma mem-
brane by virtue of the over-expression of some speciﬁc ERα
interactors. The spliced form of the metastasis tumor antigen
(MTA1s), the modulator of extra-nuclear activity of estrogen
receptor (MNAR, also known as PELP1), and activated growth
factor receptors are the prototype of such a protein (Acconcia
and Kumar, 2006). Indeed, MTA1s sequesters the ERα in the
cytoplasm, is highly expressed in ERα-negative but not in ERα-
positive breast tumors, and an increased level of MTA1s in
ERα-nuclear negative tumors is associated with the presence of
cytoplasmic ERα in tumor cells (Acconcia and Kumar, 2006).
Similarly, PELP1 functions as a scaffold that brings together the
ERα and the signaling proteins required for the activation of the
extra-nuclear E2 effects in close proximity of the plasma mem-
brane. As in the case of MTA1s, PELP1 is over-expressed in
aggressive and metastatic breast cancers (Acconcia and Kumar,
2006). Finally, the microtubule-binding protein hematopoietic
PBX-interaction protein (HPIP) also contributes to E2 extra-
nuclear signaling by recruiting the ERα and its signaling partners
in the cytoplasm of the breast cancer cells (Manavathi et al.,
2006). In addition to these extra-nuclear ERα interactors, the
de-regulation of the ERα membrane signaling might occur as a
consequence of the over-expression of speciﬁc ERα splice vari-
ants (e.g., ERα36; ERα46), which also localize into the cyto-
plasm or at the plasma membrane and hyper-activate the pro-
liferative and anti-apoptotic E2 signals (Kim and Bender, 2009;
Ohshiro et al., 2010).
It is, therefore, evident that the molecular circuitries, which
are conserved in cell lines, are also operative in a tumor environ-
ment, and the ERα membrane-initiated signals are active both in
nuclear ERα-positive and in nuclear ERα-negative breast tumors.
Consequently, although the presence of the ERβ at the plasma
membrane of tumor specimens has not yet been reported, given
the high degree of conservation in both structure and mechanism
of action of either ER isoforms, it is conceivable that ERβ express-
ing tumors also display a fraction of the receptor located at the
plasma membrane. In this respect, on the basis that membrane
ERα in tumors heavily contributes to uncontrolled proliferation
through the activation of the ERK/MAPKandAKTpathways (Kim
et al., 2006; Kampa et al., 2008; Mintz et al., 2008), ERβ in tumor
cell membrane may be associated with increased p38/MAPK acti-
vation and an increased E2-dependent apoptosis (Galluzzo et al.,
2007). In support of this hypothesis, ERβ expression is lost during
the progression of colon carcinoma and breast tumors expressing
ERβ have usually a better prognosis (Galluzzo et al., 2007; Barone
et al., 2010).
CONCLUSIONS AND PERSPECTIVES
On the basis of the ﬁndings highlighted in this review, it is clear that
the dichotomy in the ER-based signal transduction has to be over-
come. Indeed, one may envisage a dynamic integrated model of
action for the ERs inside the cell. In this model, ERs would trigger
target gene activation by trafﬁcking and signaling throughout the
different cell compartments (i.e., cell membrane, cytoplasm, and
nucleus). The cell context speciﬁc environment (e.g., ERs level and
ERs co-expression) would than contribute to the synergy between
the E2 rapid membrane signaling and nuclear ERs activity, thus
leading to speciﬁc responses to the same hormone and thus to a
different cell biological outcomes.
Although the ﬁeld is moving quickly, how the membrane-
initiated pathways impact onhumanphysiology andwhether these
pathways are relevant to our understanding of the changes occur-
ring during the development of hormone sensitive cancers still
remains to be ﬁrmly established. In this perspective, proteomic
approaches aimed at functionally classifying both the ER extra-
nuclear interactors and the ER post-translational modiﬁcations
will certainly provide a molecular map,which will help translating
the many years of research in the extra-nuclear, rapid hormonal
signaling ﬁeld (Ascenzi et al., 2006) into the possibility of new
therapeutic tools for human patho-physiology. Moreover, the def-
inition that extra-nuclear E2 effects occurs in both animal models
and tumors, besides demonstrating the complexity of the E2-
based signaling in vivo, further gives the opportunity to deﬁne
new targets for efﬁcacious interventions in humans.
As we gain a deeper understanding of the complex controls
exerted by ER and start identifying the critical players, it is likely
that some putative molecules might emerge as target candidates
for therapeutic development in the treatment of hormone-related
cancer. For example, the development of new estrogen receptor
modulators should consider whether their actions result from
binding membrane and/or nuclear ER. Thus, E2-related mole-
cules, which target a particular receptor pool, could be efﬁcacious,
but we will have to better understand the integrative nature of
their hormonal action to avoid the undesirable consequences of
this approach.
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